Clicky

PLx Pharma Inc.(PLXP)

Description: PLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.


Keywords: Biopharmaceutical Drugs Organic Compounds Acid Cardiovascular Disease Analgesics Lipid Fatty Acids Hepatotoxins Carboxylic Acids Ibuprofen Nonsteroidal Anti Inflammatory Drugs Stage Specialty Pharmaceutical Aspirin Prevention Of Cardiovascular Disease

Home Page: plxpharma.com

PLXP Technical Analysis

9 Fishers Lane
Sparta, NJ 07871
United States
Phone: 973 409 6541


Officers

Name Title
Mr. Michael J. Valentino Exec. Chairman
Ms. Natasha Giordano CEO, Pres & Director
Ms. Rita M. O'Connor CPA, CPA CFO and Head of Manufacturing & Supply Chain
Mr. Ronald R. Zimmerman Founder & Sr. Advisor
Mr. Tom Long VP of Manufacturing & Technical Operations
Ms. Janet M. Barth VP of Investor Relations & Corp. Communications
Ms. Joanne Cotignola VP of Marketing
Mr. Patrick M. Lonergan Member of Chief Exec. Officer Advisory Group
Mr. Charles Edmund Sheedy C.F.A., CFA Member of Chief Exec. Officer Advisory Group
Mr. Harris Kaplan M.B.A., MBA Member of Chief Exec. Officer Advisory Group

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.5818
Price-to-Sales TTM: 1.2902
IPO Date: 2014-03-13
Fiscal Year End: December
Full Time Employees: 16
Back to stocks